Related Experiment Video
Updated: Oct 12, 2025
14:45
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.2K
Alpha-Synuclein and Cognitive Decline in Parkinson Disease
Tian-Sin Fan1, Sam Chi-Hao Liu2, Ruey-Meei Wu2
1Department of Neurology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City 300, Taiwan.
Life (Basel, Switzerland)
|November 27, 2021
Summary
Parkinson disease (PD) involves alpha-synuclein aggregation, leading to motor and cognitive decline. This review explores the link between alpha-synuclein and cognitive impairment in PD, highlighting biomarker opportunities.
Area of Science:
- Neuroscience
- Neurology
- Pathology
Background:
- Parkinson disease (PD) is a prevalent neurodegenerative disorder in older adults.
- It is defined by alpha-synuclein protein misfolding and aggregation in the nervous system.
- Cognitive impairment is a significant non-motor symptom that worsens as PD progresses.
Purpose of the Study:
- To review the genetic and pathophysiological connections between alpha-synuclein and cognitive impairment in Parkinson disease.
- To identify potential advancements in biomarker development for PD-related cognitive decline.
Main Methods:
- Literature review of studies on alpha-synuclein, cognitive function, and Parkinson disease.
- Analysis of the correlation between alpha-synuclein pathology spread and cognitive decline.
- Exploration of genetic and pathophysiological mechanisms.
Main Results:
- Alpha-synuclein aggregation and its spread through the brain correlate with cognitive impairment in PD.
- Specific genetic and pathophysiological factors influence this relationship.
- Current understanding points to key areas for biomarker research.
Conclusions:
- Alpha-synuclein pathology is intrinsically linked to cognitive impairment in Parkinson disease.
- Further research into the genetic and pathophysiological basis can guide biomarker discovery.
- Developing reliable biomarkers is crucial for managing cognitive decline in PD.
Related Concept Videos
01:15Parkinson's Disease: Overview
819
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
819
01:37Neural Regulation
40.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K
01:26Alzheimer's Disease: Overview
735
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
735
01:24Parkinson's Disease: Treatment
440
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
440
01:22Alzheimer's Disease: Treatment
290
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
290